House Bill 309 seeks to amend Florida's drug laws by expanding the list of controlled substances, particularly focusing on synthetic cannabinoids and potent opioids. The bill includes 7-Hydroxymitragynine, concentrated at levels above 400 parts per million, in the Schedule I controlled substances list, while also exempting certain FDA-approved xylazine animal drug products from this classification. It introduces criminal penalties for the sale, manufacture, or delivery of xylazine, establishing mandatory minimum imprisonment terms and fines for trafficking based on the quantity involved. The bill modifies sections of the Florida Statutes to reflect these changes, with an effective date set for July 1, 2026.

Additionally, the bill enhances the regulation of synthetic cannabinoids by explicitly prohibiting a range of specific chemical compounds and introducing new definitions for various synthetic substances, including ADBICA and its derivatives. It aims to close legal loopholes that may have allowed for the sale of these drugs and emphasizes public safety in light of the rapid development of new synthetic drugs. The legislation also imposes severe penalties for trafficking in potent opioids and xylazine, categorizing offenses that result in overdose or serious bodily injury as felonies of the second degree. The comprehensive approach of House Bill 309 reflects ongoing concerns about the public health risks associated with these substances.

Statutes affected:
H 309 Filed: 893.13, 893.131, 893.135